Advanced

Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.

Torngren, Kristina LU ; Öhman, Jenny LU ; Salmi, Hanna ; Larsson, Johan LU and Erlinge, David LU (2013) In Cardiology 124(4). p.252-258
Abstract
Objective: The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS). Furthermore, ticagrelor inhibits adenosine reuptake and increases coronary flow reserve during adenosine infusion in man. We wanted to determine whether ticagrelor improves peripheral arterial function in patients with a previous ACS compared to patients treated with aspirin, clopidogrel, or prasugrel. Methods: 127 patients with a previous ACS (>3 months to <3 years ago) on maintenance dose of (1) no ADP blocker (n = 35); (2) clopidogrel 75 mg (n = 35); (3) prasugrel 10 mg... (More)
Objective: The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS). Furthermore, ticagrelor inhibits adenosine reuptake and increases coronary flow reserve during adenosine infusion in man. We wanted to determine whether ticagrelor improves peripheral arterial function in patients with a previous ACS compared to patients treated with aspirin, clopidogrel, or prasugrel. Methods: 127 patients with a previous ACS (>3 months to <3 years ago) on maintenance dose of (1) no ADP blocker (n = 35); (2) clopidogrel 75 mg (n = 35); (3) prasugrel 10 mg (n = 32), or (4) ticagrelor 90 mg twice daily (n = 25) were evaluated with peripheral arterial tonometry after forearm ischemia. Results: Ticagrelor improves peripheral arterial function compared to the other groups [(1) controls 1.78 ± 0.53; (2) clopidogrel 1.78 ± 0.45; (3) prasugrel 1.64 ± 0.33, and (4) ticagrelor 2.25 ± 0.54 (means ± SD)] with a significance of p < 0.01 for ticagrelor versus no ADP blocker, p < 0.01 for ticagrelor versus clopidogrel, and p < 0.001 for ticagrelor versus prasugrel. There were fewer patients with endothelial dysfunction (<1.67 reactive hyperemia index) in the ticagrelor group (12%) compared to aspirin (51%), clopidogrel (46%), and prasugrel (53%) (p < 0.01). Conclusion: Treatment with ticagrelor improves peripheral endothelial function compared to no ADP blocker, clopidogrel, or prasugrel treatment. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cardiology
volume
124
issue
4
pages
252 - 258
publisher
Karger
external identifiers
  • wos:000318193900013
  • pmid:23594617
  • scopus:84876073045
ISSN
1421-9751
DOI
10.1159/000347122
language
English
LU publication?
yes
id
061ac84a-7010-4daa-9645-a63c878f0013 (old id 3733672)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23594617?dopt=Abstract
date added to LUP
2016-04-01 10:20:48
date last changed
2019-11-26 01:42:02
@article{061ac84a-7010-4daa-9645-a63c878f0013,
  abstract     = {Objective: The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS). Furthermore, ticagrelor inhibits adenosine reuptake and increases coronary flow reserve during adenosine infusion in man. We wanted to determine whether ticagrelor improves peripheral arterial function in patients with a previous ACS compared to patients treated with aspirin, clopidogrel, or prasugrel. Methods: 127 patients with a previous ACS (&gt;3 months to &lt;3 years ago) on maintenance dose of (1) no ADP blocker (n = 35); (2) clopidogrel 75 mg (n = 35); (3) prasugrel 10 mg (n = 32), or (4) ticagrelor 90 mg twice daily (n = 25) were evaluated with peripheral arterial tonometry after forearm ischemia. Results: Ticagrelor improves peripheral arterial function compared to the other groups [(1) controls 1.78 ± 0.53; (2) clopidogrel 1.78 ± 0.45; (3) prasugrel 1.64 ± 0.33, and (4) ticagrelor 2.25 ± 0.54 (means ± SD)] with a significance of p &lt; 0.01 for ticagrelor versus no ADP blocker, p &lt; 0.01 for ticagrelor versus clopidogrel, and p &lt; 0.001 for ticagrelor versus prasugrel. There were fewer patients with endothelial dysfunction (&lt;1.67 reactive hyperemia index) in the ticagrelor group (12%) compared to aspirin (51%), clopidogrel (46%), and prasugrel (53%) (p &lt; 0.01). Conclusion: Treatment with ticagrelor improves peripheral endothelial function compared to no ADP blocker, clopidogrel, or prasugrel treatment.},
  author       = {Torngren, Kristina and Öhman, Jenny and Salmi, Hanna and Larsson, Johan and Erlinge, David},
  issn         = {1421-9751},
  language     = {eng},
  number       = {4},
  pages        = {252--258},
  publisher    = {Karger},
  series       = {Cardiology},
  title        = {Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.},
  url          = {http://dx.doi.org/10.1159/000347122},
  doi          = {10.1159/000347122},
  volume       = {124},
  year         = {2013},
}